Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

0.72EUR
3 Aug 2020
Change (% chg)

€-0.01 (-1.63%)
Prev Close
€0.74
Open
€0.72
Day's High
€0.72
Day's Low
€0.72
Volume
14,150
Avg. Vol
187,820
52-wk High
€1.34
52-wk Low
€0.48

Latest Key Developments (Source: Significant Developments)

Deinove: Phase II Trial For DNV3837 Antibiotic Candidate Continues In The US
Wednesday, 15 Jul 2020 

July 15 (Reuters) - DEINOVE SA ::DNV3837 ANTIBIOTIC CANDIDATE: THE PHASE II TRIAL CONTINUES IN THE US.DNV3837 TARGETS TREATMENT OF CLOSTRIDIOIDES DIFFICILE GASTROINTESTINAL INFECTIONS (CDI).ON CORONAVIRUS: THIS TRIAL CONTINUES IN UNITED STATES DESPITE COVID-19 OUTBREAK.  Full Article

Deinove Issues Convertible Bonds For EUR 1.5 Million
Wednesday, 17 Jun 2020 

June 17 (Reuters) - Deinove SA ::ISSUES 3RD TRANCHE OF CONVERTIBLE BONDS OF EUR 1.5 MILLION.3RD TRANCHE CONSISTS OF 150 BONDS OF NOMINAL VALUE OF EUR 10,000 EACH.BONDS FOR A MAXIMUM PERIOD OF 24 MONTHS.  Full Article

Deinove FY Group Net Loss Widens To 10.2 Million Euros
Wednesday, 29 Apr 2020 

April 29 (Reuters) - DEINOVE SA ::GROUP NET LOSS FOR 2019 EUR 10.2 MILLION, COMPARED WITH LOSS OF EUR 8.7 MILLION IN 2018, MAINLY DUE TO PROGRESS OF DNV3837 CLINICAL PROGRAM.CONSOLIDATED CASH POSITION EUR 3.0 MILLION AS OF MARCH 31, 2020.END-DEC CONSOLIDATED OPERATING LOSS OF EUR 12.2 MILLION VERSUS LOSS OF EUR 10.5 MILLION YEAR AGO.OBJECTIVES 2020: GENERATE REVENUES THROUGH COSMETICS BUSINESS, ADVANCE DNV3837 PROGRAM TOWARDS PHASE III AND MONITOR EXPENSES TO MAINTAINFINANCIAL FLEXIBILITY.INITIATION OF PHASE II TRIAL TESTING DNV3837 AS FIRST‐LINE TREATMENT FOR SEVERE C. DIFFICILE GASTROINTESTINAL INFECTIONS.  Full Article

Deinove Issues 2nd Tranche Of €1 Million of Notes Convertible Into New Shares
Friday, 3 Apr 2020 

April 3 (Reuters) - DEINOVE SA ::ISSUANCE OF A 2ND TRANCH OF €1 MILLION OF NOTES CONVERTIBLE INTO NEW SHARES.THIS SECOND TRANCHE IS COMPOSED OF 100 OCA WITH A NOMINAL VALUE OF EUR 10,000 EACH, REPRESENTING A TOTAL AMOUNT OF EUR 1,000,000, FULLY SUBSCRIBED BY THE INVESTOR TODAY, IN ACCORDANCE WITH THE CONTRACT SIGNED ON JULY 9, 2019.THE OBJECTIVES ARE TO FINANCE THE NEED FOR WORKING CAPITAL, CONTINUE THE DEVELOPMENT AND MARKETING OF NATURAL ACTIVE INGREDIENTS, PHASE II CLINICAL TRIAL IN THE UNITED STATES TESTING DNV3837, AND DISCOVER NEW ANTIBIOTIC LEADS.  Full Article

Deinove Obtains EUR 2.1 Mln From Societe Generale For 2019 R&D Tax Credit Receivable
Wednesday, 1 Apr 2020 

April 1 (Reuters) - DEINOVE SA ::DEINOVE OBTAINS FROM SOCIÉTÉ GÉNÉRALE FACTORING THE PRE-FUNDING OF ITS 2019 RESEARCH AND DEVELOPMENT TAX CREDIT RECEIVABLE AMOUNTING TO EUR 2.1 MILLION.DEINOVE RECEIVED EUR 2.1M AND THUS STRENGTHENED ITS SHORT-TERM CASH POSITION.FOR SECOND YEAR IN A ROW, DEINOVE HAS CALLED ON SOCIÉTÉ GÉNÉRALE FACTORING (SGF) TO PRE-FINANCE ITS RESEARCH AND DEVELOPMENT TAX CREDIT RECEIVABLE.  Full Article

Deinove Says Collaboration Deal Between Sharon Labs And Co To Not Be Signed
Monday, 30 Mar 2020 

March 29 (Reuters) - Deinove SA ::DEINOVE - DUE TO ECONOMIC AND INDUSTRIAL UNCERTAINTY, COLLABORATION AGREEMENT BETWEEN SHARON LABORATORIES AND CO TO NOT BE SIGNED.DEINOVE-$200,000 PAYMENT MADE BY SHARON LABORATORIES TO CO AT SIGNING OF MOU REMAINS RETAINED BY CO.  Full Article

Deinove Postpones 2019 Financial Results
Tuesday, 24 Mar 2020 

March 24 (Reuters) - DEINOVE SA ::2019 FINANCIAL RESULTS ARE POSTPONED TO APRIL 29, 2020.CHANGE IS A CONSEQUENCE OF CURRENT CONTEXT RELATED TO COVID-19 PANDEMIC.ANNUAL GENERAL MEETING IS STILL SCHEDULED FOR JUNE 16, 2020.  Full Article

Deinove Receives EUR 1.5 Mln From Bpifrance
Wednesday, 11 Mar 2020 

March 11 (Reuters) - DEINOVE SA ::DEINOVE PASSES THE 2ND MILESTONE OF THE AGIR PROGRAM AND RECEIVES €1.5M FROM BPIFRANCE.RESULTS OBTAINED VALIDATE THIS STAGE AND LEAD TO A PAYMENT OF EUR 1.5M FROM BPIFRANCE..2ND MILESTONE OF THIS RESEARCH PROGRAM INCLUDED SCREENING OF GROWING NUMBER OF STRAINS, VALIDATION OF AUTOMATED TOOLS DEVELOPED BY DEINOVE AND IDENTIFICATION OF SOME THIRTY "HITS".COMPANY HAS ENTERED INTO PARTNERSHIPS WITH SEVERAL COMPANIES, INCLUDING BIOMÉRIEUX AND NAICONS.DEINOVE AIMS TO MAXIMIZE OPPORTUNITIES TO DISCOVER NEW ANTIBIOTIC STRUCTURES BY EXPANDING ITS FIELD OF RESEARCH BEYOND ITS OWN BACTERIAL LIBRARY.  Full Article

Deinove Expands Its Range Of Cosmetic Active Ingredients
Wednesday, 19 Feb 2020 

Feb 19 (Reuters) - DEINOVE SA ::EXPANDS ITS RANGE OF COSMETIC ACTIVE INGREDIENTS.ITS SECOND INNOVATIVE CAROTENOID HAS PARTICULARITY OF ABSORBING BLUE LIGHT, WHICH IS RESPONSIBLE FOR PREMATURE SKIN AGEING, APPEARANCE OF SKIN SPOTS, LOSS OF RADIANCE AND VITALITY.EFFICACY TESTS CARRIED OUT ON HUMAN SKIN EXPLANTS CONFIRMED ITS PROTECTIVE PROPERTIES AND ALSO REVEALED THAT IT PLAYS ACTIVE ROLE ON KEY PARAMETERS CONTRIBUTING TO SKIN LIGHTENING.NEW INGREDIENT WILL BE OFFICIALLY LAUNCHED AT IN-COSMETICS GLOBAL (31 MARCH-2 APRIL, BARCELONA).  Full Article

Deinove Signs MoU With Sharon Laboratories
Thursday, 6 Feb 2020 

Feb 6 (Reuters) - Deinove SA ::SHARON LABORATORIES CAPITALIZES ON DEINOVE TO SUSTAIN ITS DEVELOPMENT ACTIVITIES.SIGNED MEMORANDUM OF UNDERSTANDING (MOU) COVERS DEVELOPMENT AND MARKETING OF AN EXCLUSIVE RANGE OF BIO-BASED INGREDIENTS FOR PERSONAL CARE FROM DEINOVE'S PLATFORM.THIS DECISIVE AND UNPRECEDENTED AGREEMENT, TO BE FINALIZED BY END OF MARCH 2020, WILL HAVE AN INITIAL TERM OF 3 YEARS AND PROVIDES FOR PARTIAL FINANCING OF ACTIVITIES AND ROYALTIES ON SALES.EVEN BEFORE CONCLUSION OF CONTRACTUAL AGREEMENT, SHARON LABORATORIES DEMONSTRATES ITS COMMITMENT WITH IMMEDIATE PAYMENT OF $200K.SHARON LABORATORIES DEMONSTRATES ITS COMMITMENT WITH IMMEDIATE PAYMENT OF $200K, BEING ONLY A PART OF SUBSTANTIAL UPFRONT PAYMENT TO BE PAID AFTER SIGNING OF FINAL AGREEMENT.  Full Article

BRIEF-Deinove FY Group Net Loss Widens To 10.2 Million Euros

* GROUP NET LOSS FOR 2019 EUR 10.2 MILLION, COMPARED WITH LOSS OF EUR 8.7 MILLION IN 2018, MAINLY DUE TO PROGRESS OF DNV3837 CLINICAL PROGRAM